The preliminary study of evaluation of embolism proportion of liver cancer based on the iFlow softwa

来源 :2016第十二届亚太介入放射学大会 | 被引量 : 0次 | 上传用户:pzbisyt
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective:Evaluate the embolism proportion of liver cancer with clinical study based on the iFlow software.Methods:30 patients with liver cancer who need selective hepatic artery embolization were collected.
其他文献
Hepatocellular carcinoma(HCC)is a major health problem worldwide.CD147 has been reported to be overexpressed in HCC and blocking CD147 expression can decrease tumor growth.
Objective:To Study the safety and efficacy of advanced pancreatic cancer treated by endovascular implantation of Iodine-125(125I)seeds strand.
Aim:To analyze prognostic factors for survival after transarterial chemoembolization(TACE)combined with microwave ablation(MWA)for hepatocellular carcinoma(HCC).
Objective:To evaluate the clinical characteristics of liver metastases of pancreatic neuroendocrine tumors(pNET)and the clinical application value of TACE combining with thermal ablation.
Background:Lactic acidosis is a common factor in many solid tumors.We aim to investigate if lactic acidosis can confer cancer cells with resistance to glucose deprivation.
Objective:To evaluate the recent clinical efficacy of transcatheter arterial chemoembolization(TACE)therapy for hepatocellular carcinoma(HCC)after embolization of embosphere combined with lipiodol.
Objective:To assess the clinical efficacy and feasibility of Y-configuration stenting combined with linear 125I seeds implantation and TACE for the treatment of HCC with portal vein tumor thrombus(PVT
Objective:To evaluate the efficacy and safety of transcatheter arterial chemoembolization(TACE)combined with microwave ablation(MWA)for intermediate-stage hepotocellular carcinoma(HCC).
Purpose:To compare the long-term clinical benefit of TACE followed by immediate CBCT(C-arm Cone Bean CT)guided RFA and TACE alone in treatment of large HCC(≥ 5cm).
Aims:This multicentric prospective randomized controlled trial aimed to evaluate the safety and effectiveness of transarterial 131I-metuximab as an adjuvant therapy after liver resection.